Skip to content

Closure of Protective Ileostomy 2 vs. 12 Weeks After TME

Closure of Protective Ileostomy 2 vs. 12 Weeks Following Total Mesorectal Excision (TME) for Rectal Surgery: Interim Analysis of a Multicentre, Randomized, Controlled Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02609451
Acronym
Closure2vs12
Enrollment
71
Registered
2015-11-20
Start date
2007-11-30
Completion date
2014-03-31
Last updated
2017-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer

Keywords

quality of life, feasibility, safety, protective ileostomy closure

Brief summary

The purpose of this study is to compare the feasibility, safety, and quality of life (QOL) in patients (pts) undergoing protective ileostomy closure after 2 weeks with a closure after 12 weeks.

Detailed description

In three surgical departments between 2007 and 2013, 72 pts with total mesorectal excision and coloanal or low colorectal anastomosis for rectal cancer were randomly assigned to closure of their protective ileostomy after 2 weeks (group A, 37 pts) or 12 weeks (group B, 35 pts). One day before planned stoma closure, the coloanal/colorectal anastomosis was checked by palpation, contrast enema via ileostomy and, in case of hazards, by proctoscopy. Perioperative data was assessed prospectively using numeric values, visual analogue scales (VAS, 0 = lowest value, 100 = highest value) and QOL-index (GQLI, max. 144 points). Complications were recorded prospectively.

Interventions

PROCEDUREIleostomy closure

Ileostomy closure at a different time point

Sponsors

Kantonsspital Liestal
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* anastomosis ≤ 5cm from anal verge * age \>18 years * informed consent * uneventful course after first operation

Exclusion criteria

* pregnancy * allergy to contrast agent * severe non-surgical complications * evident abdominal - pelvic complications

Design outcomes

Primary

MeasureTime frameDescription
Quality Of Life (GQLI - Questionnaire)6 weeksQuality Of Life Survey using the GQLI - Questionnaire

Secondary

MeasureTime frameDescription
Feasibility (via Visual Analogue Scale)intraoperativelySurgical Feasibility including blood loss, blood oozing, epifascial and intrabdominal adhesions, operating time and difference in bowel diameter
Safety as assessed by Morbidity, Mortality6 weeks, 16 weeksMorbidity, Mortality
Quality Of Life (EORTC - Questionnaire)preoperative (preOP), 6 weeks, 16 weeksQuality Of Life Survey using the EORTC - QLQ C30 - Questionnaire
Quality Of Life (GQLI - Questionnaire)preOP, 16 weeksQuality Of Life Survey using the GQLI - Questionnaire

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026